CTS-Clinical and Translational Science

Article	Citations
Gene polymorphism and prediction of toxicity to platinum‐based chemotherapy in patients with gynecologic cancer	515
Issue Information	202
Intradermal substance P as a challenge agent in healthy individuals	140
Issue Information	117
	94
ST2 and CSF‐1 as potential druggable targets of inflammatory bowel diseases: Results from two‐sample Mendelian randomization study	87
A Patient Centric Model for Vaso‐Occlusive Crises in Sickle Cell Disease—Outcomes of a Consensus Exercise Conducted Across Patients and Experts	79
Bridging Implementation Gaps in Digital Health: A Translational Research Imperative for Equitable Healthcare Innovation	71
Japanese Phase 1 Study for Global Development of Anti‐TL1A Antibody PF‐06480605: A Randomized, Placebo‐Controlled, Single‐Ascending Dose Study	70
The impact of skin color and tone on histamine iontophoresis and Doppler flowmetry measurements as a pharmacodynamic biomarker	61
A comprehensive Thai pharmacogenomics database (TPGxD‐1): Phenotype prediction and variants identification in 942 whole‐genome sequencing data	60
Pharmacokinetics of Sofosbuvir/Velpatasvir and efficacy of an alternate‐day treatment in hemodialysis patients with chronic hepatitis C infection	56
Patient, industry, and regulatory perspective on antibody‐drug conjugates dose optimization	55
Using partition analysis as a facile method to derive net clearances	51
First‐in‐human study of JNJ‐67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome	48
Lexicon for blood‐based early detection and screening: BLOODPAC consensus document	48
Expanding regulatory science: Regulatory complementarity and reliance	45
Mitigating ipatasertib‐induced glucose increase through dose and meal timing modifications	45
The Effect of Diabetes Medication on the Scores of the GNRI and CONUT Nutritional Indices: Cross‐S	43
Ubrogepant Plasma and Cerebrospinal Fluid Exposures in Participants With a History of Migraine: Findings From a Phase 1b Open‐Label Trial	41
CYP3A Genotype Is Associated With Variability in the Exposure and Clearance of the Novel Oncogenic Transcription Inhibitor Lurbinectedin	37
Pharmacokinetics and Toxicity of Dimethylacetamide and Its Metabolite in Pediatric Patients Treated With High Dose Intravenous Busulphan	37
Developing a clinical research infrastructure embedded in an academic medicine center that equitably supports future clinician scientists	37
Nontraditional Factors Influencing Cardiovascular Disease Risk: Correlation Among Framingham Risk Score, Body Composition Index, and Sleep‐Breathing Monitoring Index	37
From Lab to Clinic: Effect of Academia–Industry Collaboration Characteristics on Oncology Phase 1 Trial Entry	36

Generalizability in real‐world trials	33
Issue Information	32
First, Do No Harm: Addressing AI's Challenges With Out‐of‐Distribution Data in Medicine	32
Clinician Satisfaction With Pharmacogenomics Clinical Services at a Multistate Health System	30
	30
Perspectives on Using Pharmacogenomics to Guide Tobacco Cessation: Survey Results From an American Indian Community	29
Issue Information	29
Risk factors for the development of sepsis in patients with cirrhosis in intensive care units	29
Clinical and Economic Impact of Expanded TPMT Testing to Prevent Thiopurine‐Induced Myelosuppression in Australia: A Budget Impact Analysis	28
Glucocorticoid‐Induced Tumor Necrosis Factor Receptor Ligand: Correlation and Therapeutic Potential for Cognitive Impairment in Temporal Lobe Epilepsy	28
Comprehensive analysis of clinical and biological features in Parkinson's disease associated with the LRRK2 G2019S mutation: Data from the PPMI study	27
Radiolabelled Cyclodextrins for the Positron Emission Tomography Imaging of Breast Cancer: Preclinical Perspectives	26
Population‐based cellular kinetic characterization of ciltacabtagene autoleucel in subjects with relapsed or refractory multiple myeloma	26
Precision Antiplatelet Therapy after Percutaneous Coronary Intervention (Precision PCI) Registry – Informing optimal antiplatelet strategies	26
Exploring the discrepancies between clinical trials and real‐world data: A small‐cell lung cancer study	26
Emapalumab in Patients With Macrophage Activation Syndrome Associated With Still's Disease: A Population Pharmacokinetic/Pharmacodynamic Analysis	25
Population pharmacokinetic analysis of quizartinib in patients with newly diagnosed FLT3‐internal‐tandem‐duplication‐positive acute myeloid leukemia	25
Risk Factors Analysis of Cutaneous Adverse Drug Reactions Caused by Targeted Therapy and Immunotherapy Drugs for Oncology and Establishment of a Prediction Model	25
Surrogate Endpoints in Pivotal Clinical Trials for Drug Approval in Japan Compared to the United States	25
Phase 1 Study Evaluating the Pharmacokinetics, Dose Proportionality, Bioavailability, and Tolerability of Subcutaneous Levothyroxine Sodium (XP‐8121)	25
Feasibility study for a fully decentralized clinical trial in participants with functional constipation symptoms	25
Utilization of Machine Learning Approaches for Drug Clearance Prediction and Population Pharmacokinetic Covariate Analysis	24
Strengthening the Food and Drug Administration Office of Clinical Pharmacology's Labeling Authority	23
Efficacy and safety of tofacitinib in rheumatoid arthritis: Nine years of real‐world data	23
Pharmacokinetics and Safety of Pelacarsen, a GalNAc 3 ‐Conjugated Antise	23
Concentration–Response Analysis of the Combination of Pyronaridine and Piperaquine on Corrected QT Interval From a Randomized, Double‐Blind, Placebo‐	22
Gossypol improves myocardial dysfunction caused by sepsis by regulating histone acetylation	22
Recommended Clinical Context and Patient Context Data Elements for Liquid Biopsy Data Submitted to Data Repositories and Data Commons	22
Informing Dose for Pediatric Rare Diseases—A Survey of Recent Orphan Drugs Approvals	22
First‐in‐human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor	21
Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants	21
Prevalence of actionable pharmacogenetic variants and high‐risk drug prescriptions: A Swiss hospital‐based cohort study	21
Investigation of pharmacokinetic drug interaction between clesacostat and DGAT2 inhibitor ervogastat in healthy adult participants	21
Parkinson's disease: Still waiting for a cure	21
Diabetes Knowledge and Medication Adherence Among High‐Risk Type 2 Diabetic Patients in a Rural Area in Vietnam: A Cross‐Sectional Study	21
Human radiolabeled mass balance studies supporting the FDA approval of new drugs	21
Real‐world evidence to support regulatory submissions: A landscape review and assessment of use cases	21
Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine‐kinase inhibitors	20
Use cases of registry‐based randomized controlled trials—A review of the registries' contributions and constraints	19
Effect of Whole‐Brain Radiotherapy Dose on the Occurrence of Otitis Media and Mastoiditis in Patients With Lung Cancer With Brain Metastasis	19
Comparing machine learning and deep learning models to predict cognition progression in Parkinson's disease	19
Real‐world evidence in the cloud: Tutorial on developing an end‐to‐end data and analytics pipeline using Amazon Web Services resources	19
Effect of Selective Serotonin Reuptake Inhibitors on Coagulation: Fact or Fiction?	19
Hesitant adopters: An examination of hesitancy among adults in Arkansas who have taken the COVID‐19 vaccine	19
Transarterial Chemoembolization for Patients With Hepatocellular Carcinoma Using Miriplatin Without the Need for Hydration	19
Issue Information	19
The Role of Candidate Polymorphisms in Drug Transporter Genes on High‐Dose Methotrexate in the Consolidation Phase of the AIEOP‐BFM ALL 2009 Protocol	19
Posaconazole and midostaurin in patients with FLT3‐mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study	18
Issue Information	18
Clinical Pharmacology Overview of Tislelizumab in Patients With Advanced Tumors With a Focus on Racial Impact	18

Physiologically Based Pharmacokinetic Modeling of Valemetostat to Inform Dose Recommendations When Coadministered With CYP3A /P‐gp Modulators	18
Colonic Tissue Expression of MAdCAM ‐1 Is Not Predictive of Vedolizumab Responsiveness in Inflammatory Bowel Disease	18
Cardiovascular risk of urate‐lowering drugs: A study using the National Database of Health Insurance Claims and Specific Health Checkups of Japan	17
A Tutorial and Use Case Example of the eXtreme Gradient Boosting (XGBoost) Artificial Intelligence Algorithm for Drug Development Applications	17
Issue Information	17
Evaluation of Drug–Drug Interaction Potential Between the Oral Antibiotic Zoliflodacin and the CYP3A4 Inhibitor Itraconazole: A Phase 1 Study in Heal	17
Real‐world implementation of DPYD and UGT1A1 pharmacogenetic testing in a community‐based cancer center	17
Associations of HLA genetic variants with carbamazepine‐induced cutaneous adverse drug reactions: An updated meta‐analysis	17
	17
	17
Assessment of QT Interval Prolongation Using Concentration– QT Modeling for Iptacopan, an Oral Com	17
Pediatric CYP2D6 metabolizer status and post‐tonsillectomy nausea and vomiting after ondansetron	17
Issue Information	17
Lidocaine as an anti‐arrhythmic drug: Are there any indications left?	17
Vericiguat, a novel sGC stimulator: Mechanism of action, clinical, and translational science	17
Model‐informed precision dosing of teicoplanin for the rapid achievement of the target area under the concentration‐time curve: A simulation study	16
The Dorsal Forearm as a Novel Target for Intramuscular Injections: Clinical Pharmacokinetic Results With Naloxone	16
Issue Information	16
Alternative Dosing Regimens of Tislelizumab Using a Pharmacometrics Model‐Based Approach	16
Issue Information	16
Issue Information	16
Academia and industry agreement on a feasibility tool for first‐time‐in‐human clinical trial units	16
Mass Balance and Metabolism of 14 C ‐Atogepant in Healthy Male Participa	16
A Multicenter Randomized Controlled Study on Pharmacokinetic‐Guided Vancomycin Use in Children With Severe Infections	16
Engaging student opinions on vaccine development innovation: Experiences from a “Shark Tank” project	15
Prediction of molecular phenotypes for novel SCN1A variants from a Turkish genetic epilepsy syndromes cohort and report of two new patients with recessive Dravet syndrome	15
Characterization of Drug–Drug Interactions for Remdesivir, an Intravenous Antiviral for SARS‐CoV‐2, in Healthy Participants	15
Issue Information	15
A First‐In‐Human Phase 1 Study to Evaluate the Safety and Tolerability of LEM‐S401, a Novel siRNA‐DegradaBALL Drug Targeting CTGF in Healthy Adul	15
A Survey Study of Roadblocks in Translational Science	15
PBPK‐led assessment of antimalarial drugs as candidates for Covid‐19: Simulating concentrations at the site of action to inform repurposing strategies	15
Psoriasis Risk Is Lower in Type 2 Diabetes Patients Using Dipeptidyl Peptidase‐4 Inhibitors or Thiazolidinediones Compared to Sulfonylureas	15
Integrating real‐world data and machine learning: A framework to assess covariate importance in real‐world use of alternative intravenous dosing regimens for atezolizumab	15
Pharmacokinetic evaluation of radiolabeled intraocular anti‐CLEC14a antibody in preclinical animal species and application in humans	15
Impact of Pharmacokinetic Gene Polymorphisms on Statin‐Induced Myotoxicity in Thai Patients Treated With Simvastatin	14
Free heme and hemopexin in acute kidney injury after cardiopulmonary bypass and transient renal ischemia	14
Metabolomic signatures of carfilzomib‐related cardiotoxicity in patients with multiple myeloma	14
Association between statin use and dry eye disease in patients with hyperlipidemia: A population‐based retrospective cohort study	14
Penetration of linezolid and tedizolid in cerebrospinal fluid of mouse and impact of blood–brain barrier disruption	14
Dupilumab: Mechanism of action, clinical, and translational science	14
Preimmunization of SPF Mice With Capsid Virus‐like Particle Has no Effect on CD8 +	14
CYP2C8*3 and *4 define CYP2C8 phenotype: An approach with the substrate cinitapride	14
Insights From a User Experience‐Focused Virtual Study on the Feasibility and Challenges of Decentralized Clinical Trials	14
Issue Information	14
Machine learning framework to predict pharmacokinetic profile of small molecule drugs based on chemical structure	14
The “One‐Step” approach for QT analysis increases the sensitivity of nonclinical QTc analysis	14
Tutorial Drug–Drug Interactions	14
What motivates people with type 2 diabetes mellitus to participate in clinical trials from home?	14
First‐in‐Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP1617, a Cathepsin‐S Inhibitor, in Healthy Adult Subjects	14
Artificial intelligence in rare disease diagnosis and treatment	14
Response to “DPYD genotyping panels: Impact of population diversity”	13
Prediction of Cisplatin‐Induced Acute Kidney Injury Using an Interpretable Machine Learning Model and Electronic Medical Record Information	13
Key Stakeholders' Knowledge, Opinions, and Interests on Real‐World Evidence in the Regulatory Process—Results of an EU ‐Wide Survey	13
A Patient‐Derived 3D Cyst Model of Polycystic Kidney Disease That Mimics Disease Development and Responds to Repurposing Candidates	13
Application of Machine Learning for Predicting Progression‐Free and Overall Survival in Patients With Renal Cell Carcinoma	13
Comparison of glutaminase and cancer antigen 125 for distinguishing benign and malignant ovarian tumors	13
Cardiovascular safety of febuxostat versus allopurinol among the Asian patients with or without gout: A systematic review and meta‐analysis	13
Physiologically based absorption modeling to predict the bioequivalence of two apixaban formulations	13
Clinical pharmacokinetics and pharmacodynamics of ongericimab: A potential long‐acting PCSK9 monoclonal antibody in healthy subjects and patients with hypercholesterolemia: Randomized, double‐blind, p	13
A drug‐disease model for predicting survival in an Ebola outbreak	13
Leveraging patient‐centric sampling for clinical drug development and decentralized clinical trials: Promise to reality	13
MicroRNA sequencing in patients with coronary artery disease – considerations for use as biomarker for thrombotic risk	13
Safety, pharmacokinetics, and pharmacodynamics of ART‐648, a PDE4 inhibitor in healthy subjects: A randomized, placebo‐controlled phase I study	13
	13
Ascites affects the benefit of carvedilol on patients with liver cirrhosis and esophageal and gastric varices	13
Association of SULT2A1 Locus With Abiraterone Clearance in the Alliance A	13
Preclinical assessment of drug–drug interaction of fb‐PMT, a novel anti‐cancer thyrointegrin αvβ3 antagonist	13
Feasibility of preemptive pharmacogenetic testing and improvement of medication treatment satisfaction among medically underserved patients	13
Optimizing expert and patient input in pediatric trial design: Lessons learned and recommendations from a collaboration between conect4children and European Patient‐CEntric ClinicAl TRial PLatforms	13
Anticoagulant therapy in COVID‐19: A narrative review	12
Pharmacokinetics and safety of erenumab in pediatric patients with migraine: A phase I, randomized, open‐label, multiple‐dose study	12
Evaluation of potential drug–drug interactions with medical cannabis	12
Proposing a framework to quantify the potential impact of pharmacokinetic drug–drug interactions caused by a new drug candidate by using real world data about the target patient population	12
Effect of carrot intake on glucose tolerance, microbiota, and gene expression in a type 2 diabetes mouse model	12
Pharmacokinetics and Safety of Single and Multiple Doses of Molnupiravir in Healthy Male Chinese Adults: An Open‐Label, Fixed Sequence, Phase 1 Study	12
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INT‐787, a Novel Farnesoid X Receptor Agonist, in Healthy Volunteers: A Phase 1 Trial	12
Updated DPYDHapB3 haplotype structure and implications for pharmacogenomic testing	12
Population pharmacokinetic and pharmacodynamic modeling of evobrutinib in healthy adult participants	12
An overview of drug‐induced sodium channel blockade and changes in cardiac conduction: Implications for drug safety	12
Issue Information	12

Trial of Preemptive Pharmacogenetic Testing in Underserved Patients ( TOPP UP ): Study Framework and Baseline Characteristics of Randomized Controlle	12
Association between aortic calcification and cytokine levels in patients with peripheral artery disease	12
Correction to “Enhanced Clearance of HIV ‐1 Broadly Neutralizing Antibody VRC07 ‐523‐	12
Critical Roles for Modeling and Simulation and Real‐World Evidence to Inform Challenges in Clinical Trial Diversity Planning	12
Issue Information	12
	11
Subtyping treatment response of tirofiban in acute ischemic stroke based on neuroimaging features	11
No drug–drug interactions between selective prolyl‐tRNA synthetase inhibitor, bersiporocin, and pirfenidone or nintedanib in healthy participants	11
Use of Biomarkers in Drug Development for Regulatory Purposes	11
Informing Implementation Strategies for Pharmacogenomics in Cancer: Development of Survey Tools for Healthcare Professionals and Consumers	11
How AI Transforms Regulatory Submission: Current Clinical Implementation and Future Prospects	11
Inhibition of Tacrolimus Metabolism by Cannabidiol and Its Metabolites In Vitro	11
A randomized, controlled trial of prulifloxacin as conversion therapy after intravenous carbapenem in the treatment of acute pyelonephritis caused by third generation cephalosporin resistant pathogens	11
Association of Vancomycin Plus Piperacillin‐Tazobactam With Acute Kidney Injury: Differentiating Pseudo‐Injury From True Nephrotoxicity	11
Clinical Pharmacology Approaches to Predict Efficacy of Monoclonal Antibodies Against Emerging SARS ‐ CoV	11
Generic substitution of amlodipine is not associated with increased risk of mortality or adverse cardiovascular events: An observational cohort study	11
Pharmacokinetics, pharmacodynamics, and safety of frunexian in healthy Chinese volunteer adults: A randomized dose‐escalation phase I study	11
A phase I randomized, double‐blind, single subcutaneous dose escalation study to determine the safety, tolerability, and pharmacokinetics of rezafungin in healthy adult subjects	11
Atogepant: Mechanism of action, clinical and translational science	11
Potential biomarkers for fatal outcome prognosis in a cohort of hospitalized COVID ‐19 patients with pre‐existing comorbidities	11
	11
Evolution of preclinical characterization and insights into clinical pharmacology of checkpoint inhibitors approved for cancer immunotherapy	11
Remimazolam versus propofol in combination with esketamine for surgical abortion: A double‐blind randomized controlled trial	11
An exploratory machine learning approach to identify placebo responders in pharmacological binge eating disorder trials	11
Issue Information	11
Postmarket safety communications on drugs approved in Japan: A 25‐year analysis	11
Cardiac sodium channel inhibition by lamotrigine: In vitro characterization and clinical implications	11
Drug Interaction PBPK Modeling: Review of the Literature Exposes the Need for Increased Verification of Model Inputs and Outputs as Part of Credibility Assessment	10
Efficacy, safety, and pharmacokinetics of isoniazid affected by NAT2 polymorphisms in patients with tuberculosis: A systematic review	10
Population pharmacokinetics of iruplinalkib in healthy volunteers and patients with solid tumors	10
Safety, Tolerability, and Pharmacokinetics of NIM‐1324 an Oral LANCL2 Agonist in a Randomized, Double‐Blind, Placebo‐Controlled Phase I Clinical Trial	10
Issue Information	10
Inflammation altered correlation between CYP2C19 genotype and CYP2C19 activity in patients receiving voriconazole	10
Pharmacokinetics and Safety of Fixed‐Dose Versus Separate Enavogliflozin/Gemigliptin Combinations, and Food Effect on Enavogliflozin in Healthy Korean Subjects	10
Surfing the T Wave: A Primer on ECG T Wave Morphologies Encountered in Clinical Trials and Impact on the QT Interval and Patient Safety	10
Age‐related off‐label drug prescribing in pediatric patients in South Korea and consistency of labeling compared to the United States, Europe, and Japan	10
Exploratory Evaluation of Solanidine as an Endogenous Marker for CYP2D6 ‐Mediated Drug–Drug–Gene Interactions of Venlafaxine in Koreans	10
Differential effects of metformin‐mediated BSEP repression on pravastatin and bile acid pharmacokinetics in humans: A randomized controlled trial	10
Association between serum albumin to serum creatinine ratio and mortality risk in patients with heart failure	10
Proteomics Used in Identifying Novel Correlates of Disease in Pediatric Metabolic Dysfunction‐Associated Steatotic Liver Disease	10
A naïve pooled data approach for extrapolation of Phase 0 microdose trials to therapeutic dosing regimens	10
Regulation of exosomes as biologic medicines: Regulatory challenges faced in exosome development and manufacturing processes	10
AAV Gene Therapy Drug Development and Translation of Engineered Ocular and Neurotropic Capsids: A Systematic Review Using Natural Language Processing	10
Decentralized Clinical Trials in the Era of Real‐World Evidence: A Statistical Perspective	10
High‐Frequency, At‐Home Monitoring of Drug Safety and Tolerability in Clinical Trials: Results From Studies of Fluvoxamine for COVID ‐19 Treatment	10
Opportunities and challenges of 5G network technology toward precision medicine	10
Large‐Scale Analysis of Age and Sex Effects on Corrected QT and JT Intervals: Insights From Hospital‐Based Controls and Moxifloxacin‐Treated Cases	10
A longitudinal study of cytochrome P450 2D6 (CYP2D6) activity during adolescence	10
	10
Standardization, Education, and Resourcing: The Way Forward for Implementing Polygenic Risk Scores in Hereditary Breast and Ovarian Cancer	10
Changing the drug development and therapeutic paradigm with biologic drug combinations and bispecifics: How to choose between these two approaches?	10
Global harmonization of immediate‐release solid oral drug product bioequivalence recommendations and the impact on generic drug development	10
Controlled oxygenated rewarming as novel end‐ischemic therapy for cold stored liver grafts. A randomized controlled trial	9
	9
Using exploratory pharmacokinetic and pharmacodynamic analyses to predict the probability of flu‐like symptoms in healthy volunteers and patients with chronic hepatitis B treated with the toll‐like re	9
Association of Protocol Design‐Related Factors With Enrollment Duration in Clinical Trials	9
Issue Information	9
Clinical Characteristics, Molecular Diagnosis, and Drug Resistance Profiles of Nontuberculous Mycobacteria Infections: A Retrospective Analysis Using PCR	9
First‐In‐Human, Randomized, Placebo‐Controlled, SAD and MAD Trial to Evaluate Safety, Tolerability, and PK/PD Modeling of Potravitug in Healthy Adults	9
Application of Machine Learning to Discriminate Photoreceptor Cell Species in Xenotransplanted Chimeric Retinas	9
A linked physiologically based pharmacokinetic model for hydroxychloroquine and metabolite desethylhydroxychloroquine in SARS‐CoV‐2(−)/(+) populations	9
BLOODPAC: Collaborating to chart a path towards blood‐based screening for early cancer detection	9
Population‐Based Modeling to Predict Human PK / PD of TAK	9
Re‐discover the value of protein binding assessments in hepatic and renal impairment studies and its contributions in drug labels and dose decisions	9
Pharmacokinetics of Bocidelpar, ASP0367, in Renal and Hepatic Impairment: Results From Two Phase 1 Studies	9
Pharmacogenomic and Clinical Predictors of Deferasirox Response in Transfusion‐Dependent Thalassemia Identified Using Whole‐Genome Sequencing	9
Muscle velocity recovery cycles as pharmacodynamic biomarker: Effects of mexiletine in a randomized double‐blind placebo‐controlled cross‐over study	9
In Vitro Diagnostics for SARS ‐ CoV ‐2 Infection Authorized in the United States and Approved in J	9
Translational Pharmacokinetic‐Pharmacodynamic Modeling and Efficacious Human Dose Prediction of DNDI ‐6148 for the Treatment of Cutaneous Leishmanias	9
Pharmacokinetic comparison of subcutaneously administered CT‐P13 (biosimilar of infliximab) via autoinjector and pre‐filled syringe in healthy participants	8
Pharmacokinetics, pharmacodynamics, and safety of fesomersen, a novel antisense inhibitor of factor XI, in healthy Chinese, Japanese, and Caucasian volunteers	8
Pacific Blue Derivatives of Paclitaxel as Fluorescent Probes of OATP1B‐Type Transporters	8
	8
Tutorial: Microbiome studies in drug metabolism	8
Predicting Vancomycin Clearance in Neonates and Infants by Integrating Machine Learning and Metabolomics With Population Pharmacokinetics	8
Association between psychomotor function and ALDH2 genotype after consuming barley shochu: A randomized crossover trial	8
The expanding universe of NUTM1 fusions in pediatric cancer	8
Biolink Model: A universal schema for knowledge graphs in clinical, biomedical, and translational science	8
Safety, Pharmacokinetics, and Immunogenicity of Astegolimab, an Anti‐ST2 Monoclonal Antibody, in Randomized, Phase I Clinical Studies	8
Dicloxacillin and Flucloxacillin Inhibit Hepatic Uptake Transporters—In Vitro Investigations and Physiologically Based Pharmacokinetic Modeling	8
Optimizing a therapy for opiate use disorders: Characterizing ondansetron pharmacokinetics in blood and brain	8
	8
Pharmacokinetics of apixaban and tacrolimus or cyclosporine in kidney and lung transplant recipients	8
	8
Pharmacogenetics of tamoxifen in breast cancer patients of African descent: Lack of data	8
Evaluation of Innate Immune System, Body Habitus, and Sex on the Pharmacokinetics and Pharmacodynamics of Anetumab Ravtansine in Patients With Cancer	8
Pharmacogenomic variation and sedation outcomes during early intensive care unit admission: A pragmatic study	8
Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo‐controlled,	8
Thai pharmacogenomics database −2 (TPGxD‐2) sequel to TPGxD‐1, analyzing genetic variants in 26 non‐VIPGx genes within the Thai population	8
Umbilical cord blood–derived exosomes from healthy term pregnancies protect against hyperoxia‐induced lung injury in mice	8
Issue Information	8
Integrating Sustainability Pillars Into Trial Design Decision‐Making: Results of an International Survey	8
Translational findings support regimen selection for first‐in‐human study of ubamatamab (MUC16 × CD3 bispecific antibody) in patients with recurrent ovarian cancer	8
Evaluating the Effect of Epigallocatechin Gallate (EGCG) in Reducing Folate Levels in Reproductive Aged Women by MTHFR and DHFR Genotype in Combination With Letrozole	8
Pharmacokinetics and Safety of Polaprezinc Granules Oral Administration in Healthy Chinese Volunteers Under Fasting and Fed Conditions	8